Tonix Pharmaceuticals to Present Poster at EULAR 2024

Tonix Pharmaceuticals, Inc., a fully-integrated biopharmaceutical company, recently announced its participation in the Annual European Congress of Rheumatology (EULAR) 2024, taking place from June 12-15 at the Messe Wien Congress Center in Vienna, Austria. The company will present a poster highlighting the significant Phase 3 results of their investigational drug, Tonmya™ (TNX-102 SL), for the management of fibromyalgia.

The presentation will be delivered by Dr. Iredell Iglehart, under the title "Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial." This session is scheduled for Friday, June 14, 2024, at 12:36 p.m. CEST during the Poster Tour 2 session. The abstract for the presentation is listed as POS0324.

Tonix Pharmaceuticals aims to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Tonmya™ in the latter half of 2024. This submission is backed by two statistically significant Phase 3 studies demonstrating the efficacy of TNX-102 SL in managing fibromyalgia symptoms. Besides fibromyalgia, TNX-102 SL is also under development for treating acute stress reactions and fibromyalgia-type Long COVID.

In addition to TNX-102 SL, Tonix’s portfolio includes various candidates targeting central nervous system (CNS) disorders. One notable candidate is TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication, which holds Breakthrough Therapy designation. Another significant product in their immunology pipeline is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154). This biologic is being developed to prevent organ transplant rejection and treat autoimmune diseases.

Tonix also focuses on rare and infectious diseases. Their commercial subsidiary, Tonix Medicines, markets migraine treatments Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), which are used to address acute migraines in adults.

Overall, Tonix Pharmaceuticals is committed to advancing its diverse pipeline through rigorous clinical trials and regulatory submissions, with the ultimate goal of providing new therapeutic options for various medical conditions. Through their participation in significant scientific conferences like EULAR, the company continues to share valuable data and engage with the broader medical and scientific community.